BehindLines

A blood test could one day help spot the brain disease CTE

· BehindLines newsroom

Researchers from Boston University and Banner Health, based in Phoenix, describe a lead for detecting, in a living person, an advanced form of chronic traumatic encephalopathy (CTE). The study appeared on Thursday, November 19, in the journal JAMA, according to CBS Boston and the local channel AZFamily.

A diagnosis that is posthumous today

According to CBS Boston, this degenerative brain disease, linked to repeated blows to the head, can only be confirmed with certainty after death, by examining the brain. It has been observed in American football players, other athletes, military personnel and first responders. AZFamily says for its part that until now an exact diagnosis was possible only once the person had died, by looking directly at brain tissue.

What the study compared

The team worked on the blood of 21 former American football players: all had given blood while alive, then left their brains, after death, to the brain bank of Boston University's CTE Center. Eighteen of them had CTE, CBS Boston specifies. The researchers measured in the blood a form of the tau protein, which builds up in the brain in this disease and in Alzheimer's disease. According to CBS Boston and AZFamily, levels were clearly higher in players with an advanced form than in those at an early stage or without CTE.

Cautious authors

Michael Alosco, a co-author of the study, calls it "a real study of hope" and, according to AZFamily, judges that it could be a game changer if later studies back up the results; he stresses that this is still the discovery phase, with a small sample. Nicholas Ashton, of Banner Health, recalls that the blood tests already approved for Alzheimer's disease have been "revolutionary" for diagnosis and for designing trials, and says he is optimistic the same will hold for CTE. The researchers acknowledge several limitations, AZFamily reports: a small sample, few early-stage cases and no age-matched control group. Another study, published on November 13 in JAMA by a different research group, also found a form of this protein raised in people whose CTE had been confirmed at autopsy, according to AZFamily.

Why it matters

According to Alosco, quoted by AZFamily, if later studies back up these results, such a test would be able to detect CTE very accurately and would pave the way for clinical trials and treatments. For now, the test is not approved by the FDA, the US health regulator, is not available to the public and, according to the researchers cited by AZFamily, should not guide any diagnosis until validation studies have been completed. These results are preliminary.

Sources